Target: Inflammatory Diseases
 
Atreaon

Atreaon, Inc., is a privately held biopharmaceutical company developing a novel engineered protein called Atsttrin, for the treatment of inflammatory diseases such as rheumatoid arthritis. Atreaon recently completed a $20 million Series A financing to support the pre-clinical development of Atsttrin.

 

Please tell us the best way to reach you and we'll be happy to get in touch with more information.

Name:
Company:
Telephone:
Email Address:
Comments:
Please type the code shown in the image: *
©2011 Atreaon, Inc.